C4X Discovery Holdings' PLC (LON:C4XD) CEO Clive Dix talks to Proactive London about taking over as the interim chair of the UK Vaccine Taskforce following the departure of Kate Bingham.
Dix goes on to discuss how this appointment will impact C4X, explaining 'if you look at what we've achieved at C4X in the last year, I don't think you'll see a blemish on that productivity'.
Moving on to the latest results, Dix says 'it's been a really good year', with progress on all four of their key programmes including Indivior, for the treatment of opioid dependence, their inflammatory bowel disease drug, the psoriasis programme and the treatment of IBD.
After the £15mln raise earlier in the year, Dix says 'this puts us financially in a very very secure position'.
With reference to their four key programs, Dix says it's about the 'right data, the right time, to get to the right partner'.
